Posted by Michael Wonder on 14 Nov 2019
NICE ‘OK’ for Sativex in MS
14 November 2019 - NICE has recommended Bayer’s Sativex (delta-9 tetrahydrocannabinol cannabidiol), for spasticity in people with multiple sclerosis.
The cannabis-based medicinal product has been approved within its licensed indication, as the organisation deemed it clinically and cost effective at its current list price. NICE also updated the multple sclerosis guideline to state that Sativex should be offered to treat spasticity in people with the disorder.
The news follows a previous positive health technology appraisal of the treatment in spasticity by the All Wales Medicines Strategy Group.
